IP Library Granted Patent US 8,883,506
Granted Patent B2
US 8,883,506 · App. 13/590,902 · Granted Nov 11, 2014

Kits comprising linear DNAs for sustained polypeptide expression using synthetic, modified RNAs

Inventors: Derrick Rossi (Roslindale, MA); Luigi Warren (Cambridge, MA)
Assignee: Children's Medical Center Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,506
App. No.
13/590,902
Granted
Nov 11, 2014
Kind
B2
Abstract

Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.

Claims (13)

1. A kit for making synthetic mRNAs for the production of induced pluripotent stem (iPS) cells comprising the following components:

(a) a linear DNA template for the generation of a synthetic modified RNA, the template encoding an OCT4 mRNA of SEQ ID NO: 788;

(b) a linear DNA template for the generation of a synthetic modified RNA, the template encoding a SOX2 mRNA of SEQ ID NO: 941 or SEQ ID NO: 1501;

(c) a linear DNA template for the generation of a synthetic modified RNA, the template encoding a KLF4 mRNA of SEQ ID NO: 501;

(d) a linear DNA template for the generation of a synthetic modified RNA, the template encoding a c-MYC mRNA of SEQ ID NO: 636; and

(e) a ribonucleoside mixture component comprising 5-methylcytidine and pseudouridine.

2. The kit of claim 1 , wherein a T7 promoter is operably linked upstream of each of the linear DNAs encoding the OCT4 mRNA, SOX2 mRNA, KLF4 mRNA, and c-MYC mRNA.

3. The kit of claim 1 , wherein the ribonucleoside mixture further comprises a 5′ cap analog nucleoside component.

4. The kit of claim 3 , wherein the 5′ cap analog is 3″-0-Me-m 7 G(5′)ppp(5′)G.

5. The kit of claim 1 , further comprising a phosphatase enzyme, an RNA polymerase enzyme, or both.

6. The kit of claim 1 , further comprising a buffer.

7. The kit of claim 1 , further comprising a linear DNA template for the generation of a synthetic modified RNA, the template encoding a sequence encoding a soluble interferon receptor.

8. The kit of claim 7 , wherein the soluble interferon receptor is B18R.

Assignments (2)
MERGER Recorded Dec 19, 2013
From: IMMUNE DISEASE INSTITUTE, INC.
To: THE CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 031823/0095 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2013
From: THE CHILDREN'S HOSPITAL CORPORATION
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 031823/0132 →
Continuity (4)
Continuation 13088009 · Apr 15, 2011
Provisional Application 61325003 · Apr 16, 2010
Provisional Application 61387220 · Sep 28, 2010
Related Publication 20120322865A1 · Dec 20, 2012